Orexin A (Human, Rat, Mouse, Porcine, Ovine, Bovine, Monkey) – RIA Kit

Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson’s disease.
Bridoux A, Moutereau S, Covali-noroc A, et al. Nat Sci Sleep. 2013;5:87-91.

Early and persistent up-regulation of hypothalamic orexigenic peptides in rat offspring born to dams fed a high-carbohydrate supplement during gestation.
Beck B, Richy S, Archer ZA, Mercer JG. Brain Res. 2012;1477:10-8.

The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus.
Nocjar C, Zhang J, Feng P, Panksepp J. Neuroscience. 2012;218:138-53.

Hypocretin (orexin) loss in Alzheimer’s disease.
Fronczek R, Van geest S, Frölich M, et al. Neurobiol Aging. 2012;33(8):1642-50.

The effect of clomipramine on wake/sleep and orexinergic expression in rats.
Feng P, Hu Y, Li D, et al. J Psychopharmacol (Oxford). 2009;23(5):559-66.

Satiety signalling histaminergic system and brain-gut peptides in regulation of food intake in rats with portocaval anastomosis.
Fogel WA, Stasiak A, Lewinski A, Maksymowicz M, Jochem J. J Physiol Pharmacol. 2008;59 Suppl 2:135-44.

Onset of feeding at birth–perinatal development of the hypothalamic mechanisms that induce appetite and feeding in the newborn.
Dickinson H, Walker DW, Castillo-melendez M. Neurosci Lett. 2008;436(1):1-6.

Hypocretin and human African trypanosomiasis.
Dauvilliers Y, Bisser S, Chapotot F, et al. Sleep. 2008;31(3):348-54.

Analysis of cerebrospinal fluid inflammatory mediators in chronic complex regional pain syndrome related dystonia.
Munts AG, Zijlstra FJ, Nibbering PH, et al. Clin J Pain. 2008;24(1):30-4.

Increasing length of wakefulness and modulation of hypocretin-1 in the wake-consolidated squirrel monkey.
Zeitzer JM, Buckmaster CL, Lyons DM, Mignot E. Am J Physiol Regul Integr Comp Physiol. 2007;293(4):R1736-42.

Brain orexins and wake regulation in rats exposed to maternal deprivation.
Feng P, Vurbic D, Wu Z, Strohl KP. Brain Res. 2007;1154:163-72.

Hypocretin (orexin) loss in Parkinson’s disease.
Fronczek R, Overeem S, Lee SY, et al. Brain. 2007;130(Pt 6):1577-85.

Role of dorsal vagal motor nucleus orexin-receptor-1 in glycemic responses to acute versus repeated insulin administration.
Paranjape S, Vavaiya K, Kale A, Briski K. Neuropeptides. 2007;41(2):111-6.

HLA-DQB1 allele and hypocretin in Korean narcoleptics with cataplexy.
Jeong JH, Hong SC, Shin YK, Han JH, Lee SP. J Korean Med Sci. 2007;22(1):127-31.

Central and/or peripheral immunoreactivity of orexin-A in pregnant rats and women.
Sun G, Tian Z, Yao Y, Li H, Higuchi T. J Mol Endocrinol. 2006;36(1):131-8.

CSF hypocretin-1/orexin-A concentrations in patients with subarachnoid hemorrhage (SAH).
Dohi K, Ripley B, Fujiki N, et al. Peptides. 2005;26(11):2339-43.

Orexin loss in Huntington’s disease.
Petersén A, Gil J, Maat-schieman ML, et al. Hum Mol Genet. 2005;14(1):39-47.

Plasma and hypothalamic peptide-hormone levels regulating somatotroph function and energy balance in fed and fasted states: a comparative study in four strains of rats.
Kappeler L, Zizzari P, Grouselle D, Epelbaum J, Bluet-pajot MT. J Neuroendocrinol. 2004;16(12):980-8.

Convergence of circadian and sleep regulatory mechanisms on hypocretin-1.
Deboer T, Overeem S, Visser NA, et al. Neuroscience. 2004;129(3):727-32.

Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness.
Baumann CR, Dauvilliers Y, Mignot E, Bassetti CL. Eur Neurol. 2004;52(2):73-6.

Relationship between CSF hypocretin levels and hypocretin neuronal loss.
Gerashchenko D, Murillo-rodriguez E, Lin L, et al. Exp Neurol. 2003;184(2):1010-6.

Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness.
Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E. J Neurosci. 2003;23(8):3555-60.

Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia.
Ebrahim IO, Sharief MK, De lacy S, et al. J Neurol Neurosurg Psychiatr. 2003;74(1):127-30.

The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
Mignot E, Lammers GJ, Ripley B, et al. Arch Neurol. 2002;59(10):1553-62.

Release of hypocretin (orexin) during waking and sleep states.
Kiyashchenko LI, Mileykovskiy BY, Maidment N, et al. J Neurosci. 2002;22(13):5282-6.

Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities.
Yoshida Y, Fujiki N, Nakajima T, et al. Eur J Neurosci. 2001;14(7):1075-81.

Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.
Nishino S, Ripley B, Overeem S, et al. Ann Neurol. 2001;50(3):381-8.

Hypocretin levels in sporadic and familial cases of canine narcolepsy.
Ripley B, Fujiki N, Okura M, Mignot E, Nishino S. Neurobiol Dis. 2001;8(3):525-34.

Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation.
Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S. Neuroreport. 2001;12(5):993-7.

A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.
Peyron C, Faraco J, Rogers W, et al. Nat Med. 2000;6(9):991-7.